• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    MT-103 Micromet/MedImmune.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Cheadle, Eleanor J
    Affiliation
    Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uk
    Issue Date
    2006-02
    
    Metadata
    Show full item record
    Abstract
    Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
    Citation
    MT-103 Micromet/MedImmune. 2006, 8 (1):62-8 Curr. Opin. Mol. Ther.
    Journal
    Current Opinion in Molecular Therapeutics
    URI
    http://hdl.handle.net/10541/72697
    PubMed ID
    16506527
    Type
    Article
    Language
    en
    ISSN
    1464-8431
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Blinatumomab for the treatment of B-cell lymphoma.
    • Authors: Oak E, Bartlett NL
    • Issue date: 2015 May
    • Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    • Authors: Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ
    • Issue date: 2015 Sep
    • CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    • Authors: Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA
    • Issue date: 2007 Mar
    • Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    • Authors: Dahl J, Mace M, Kantarjian H, Jabbour E
    • Issue date: 2015 Apr
    • Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    • Authors: Wu J, Fu J, Zhang M, Liu D
    • Issue date: 2015 Sep 4
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.